Preeclampsia Is Associated with Lower Production of Vascular Endothelial Growth Factor by Peripheral Blood Mononuclear Cells

2000, Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, Am J Obstet Gynecol, 183, S1, 10.1067/mob.2000.107928 Sibai, 2005, Pre-eclampsia, Lancet, 365, 785, 10.1016/S0140-6736(05)71003-5 Steegers, 2010, Pre-eclampsia, Lancet, 376, 631, 10.1016/S0140-6736(10)60279-6 Roberts, 2001, Pathogenesis and genetics of pre-eclampsia, Lancet, 357, 53, 10.1016/S0140-6736(00)03577-7 Sibai, 2005, Diagnosis, prevention, and management of eclampsia, Obstet Gynecol, 105, 402, 10.1097/01.AOG.0000152351.13671.99 2002, ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002, Obstet Gynecol, 99, 159 Kendall, 1993, Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor, Proc Natl Acad Sci USA, 90, 10705, 10.1073/pnas.90.22.10705 Ferrara, 2001, Role of vascular endothelial growth factor in regulation of physiological angiogenesis, Am J Physiol Cell Physiol, 280, C1358, 10.1152/ajpcell.2001.280.6.C1358 Levine, 2006, Soluble endoglin and other circulating antiangiogenic factors in preeclampsia, N Engl J Med, 355, 992, 10.1056/NEJMoa055352 Koga, 2003, Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia, J Clin Endocrinol Metab, 88, 2348, 10.1210/jc.2002-021942 Levine, 2005, Circulating angiogenic factors in preeclampsia, Clin Obstet Gynecol, 48, 372, 10.1097/01.grf.0000160313.82606.d7 Maynard, 2003, Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, J Clin Invest, 111, 649, 10.1172/JCI17189 Molvarec, 2010, Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia, Hypertens Res, 33, 892, 10.1038/hr.2010.92 Levine, 2004, Circulating angiogenic factors and the risk of preeclampsia, N Engl J Med, 350, 672, 10.1056/NEJMoa031884 Sugimoto, 2003, Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria, J Biol Chem, 278, 12605, 10.1074/jbc.C300012200 Tsatsaris, 2003, Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences, J Clin Endocrinol Metab, 88, 5555, 10.1210/jc.2003-030528 Chaiworapongsa, 2004, Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award, Am J Obstet Gynecol, 190, 1541, 10.1016/j.ajog.2004.03.043 Shibata, 2005, Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor, J Clin Endocrinol Metab, 90, 4895, 10.1210/jc.2004-1955 Yancopoulos, 2000, Vascular-specific growth factors and blood vessel formation, Nature, 407, 242, 10.1038/35025215 de Vries, 1992, The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor, Science, 255, 989, 10.1126/science.1312256 Robinson, 2001, The splice variants of vascular endothelial growth factor (VEGF) and their receptors, J Cell Sci, 114, 853, 10.1242/jcs.114.5.853 Terman, 1992, Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor, Biochem Biophys Res Commun, 187, 1579, 10.1016/0006-291X(92)90483-2 Galland, 1993, The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor, Oncogene, 8, 1233 Hornig, 2000, Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids, Lab Invest, 80, 443, 10.1038/labinvest.3780050 Polliotti, 2003, Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia, Obstet Gynecol, 101, 1266, 10.1016/S0029-7844(03)00338-7 Taylor, 2003, Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies, Am J Obstet Gynecol, 188, 177, 10.1067/mob.2003.111 Zhou, 2002, Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome, Am J Pathol, 160, 1405, 10.1016/S0002-9440(10)62567-9 Eremina, 2003, Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases, J Clin Invest, 111, 707, 10.1172/JCI17423 Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491 Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066 Kendall, 1996, Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR, Biochem Biophys Res Commun, 226, 324, 10.1006/bbrc.1996.1355 Vuorela, 2003, Expression of vascular endothelial growth factor in peripheral blood cells of preeclamptic women, Hypertens Pregnancy, 22, 193, 10.1081/PRG-120021065 Rajakumar, 2005, Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women, Placenta, 26, 563, 10.1016/j.placenta.2004.09.001 Makris, 2007, Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1, Kidney Int, 71, 977, 10.1038/sj.ki.5002175 Lin, 2006, Macrophages regulate the angiogenic switch in a mouse model of breast cancer, Cancer Res, 66, 11238, 10.1158/0008-5472.CAN-06-1278 Molvarec, 2010, Decreased proportion of peripheral blood vascular endothelial growth factor-expressing T and natural killer cells in preeclampsia, Am J Obstet Gynecol, 203, 567.e1, 10.1016/j.ajog.2010.07.019 Hernandez-Andrade, 2002, Uterine artery score and perinatal outcome, Ultrasound Obstet Gynecol, 19, 438, 10.1046/j.1469-0705.2002.00665.x Espinoza, 2007, Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor, Am J Obstet Gynecol, 196, 326.e1, 10.1016/j.ajog.2006.11.002 Papageorghiou, 2004, The role of uterine artery Doppler in predicting adverse pregnancy outcome, Best Pract Res Clin Obstet Gynaecol, 18, 383, 10.1016/j.bpobgyn.2004.02.003 Plasencia, 2008, Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia, Ultrasound Obstet Gynecol, 32, 138, 10.1002/uog.5402 Yu, 2008, Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age, Ultrasound Obstet Gynecol, 31, 310, 10.1002/uog.5252 Scazzocchio, 2011, Contemporary prediction of preeclampsia, Curr Opin Obstet Gynecol, 23, 65, 10.1097/GCO.0b013e328344579c Leanos-Miranda, 2007, Protein:creatinine ratio in random urine samples is a reliable marker of increased 24-hour protein excretion in hospitalized women with hypertensive disorders of pregnancy, Clin Chem, 53, 1623, 10.1373/clinchem.2007.089334 Leanos-Miranda, 2008, Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes, J Clin Endocrinol Metab, 93, 2492, 10.1210/jc.2008-0305 Avery, 2005, 1659 Chaiworapongsa, 2005, Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia, J Matern Fetal Neonatal Med, 17, 3, 10.1080/14767050400028816 Park, 2005, An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia, Am J Obstet Gynecol, 193, 984, 10.1016/j.ajog.2005.06.033 Lim, 2008, Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors, Obstet Gynecol, 111, 1403, 10.1097/AOG.0b013e3181719b7a Gleicher, 2007, Why much of the pathophysiology of preeclampsia-eclampsia must be of an autoimmune nature, Am J Obstet Gynecol, 196, 5.e1, 10.1016/j.ajog.2006.09.016 Sasaki, 2007, Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in pre-eclampsia, Clin Exp Immunol, 149, 139, 10.1111/j.1365-2249.2007.03397.x Darmochwal-Kolarz, 2012, The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia, J Reprod Immunol, 93, 75, 10.1016/j.jri.2012.01.006 Dang, 2011, Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1, Cell, 146, 772, 10.1016/j.cell.2011.07.033 Darmochwal-Kolarz, 2007, Activated T lymphocytes in pre-eclampsia, Am J Reprod Immunol, 58, 39, 10.1111/j.1600-0897.2007.00489.x Toldi, 2012, The frequency of peripheral blood CD4+ CD25high FoxP3+ and CD4+ CD25- FoxP3+ regulatory T cells in normal pregnancy and pre-eclampsia, Am J Reprod Immunol, 68, 175, 10.1111/j.1600-0897.2012.01145.x Toldi, 2011, Increased prevalence of IL-17-producing peripheral blood lymphocytes in pre-eclampsia, Am J Reprod Immunol, 66, 223, 10.1111/j.1600-0897.2011.00987.x Ashur-Fabian, 2012, Cell free expression of hif1alpha and p21 in maternal peripheral blood as a marker for preeclampsia and fetal growth restriction, PLoS One, 7, e37273, 10.1371/journal.pone.0037273 Lin, 2007, Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages, Mol Oncol, 1, 288, 10.1016/j.molonc.2007.10.003